Continuous Glucose Monitor Drug Delivery Patent Landscape
Continuous Glucose Monitor Drug Delivery Patent Landscape in 2026
The continuous glucose monitor drug delivery patent space is highly concentrated, with Insulet Corp holding a commanding position among a small cohort of filers in a corpus of 20 patent families. The field entered a rapid expansion phase from 2021, though annual volume has eased from its 2022 peak and the most recent years remain understated by publication lag.
Insulet Corp dominates a nascent, highly concentrated field
Insulet Corp ranks first with 19 patent families, effectively controlling the intellectual property landscape for CGM-integrated drug delivery among the filers identified in this corpus.
The top five filers account for the entirety of the hundred largest filers’ combined total, reflecting an extreme concentration with virtually no competitive tier below the leader. P S R Engineering College and the University of Virginia. Patent Foundation each hold a single patent family, forming a distant second tier.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Insulet Corporation | 19 | |
| 2 | P S R Engineering College | 1 | |
| 3 | University of Virginia Patent Foundation | 1 |
Insulet Corp’s near-total share implies that any new entrant or challenger would be operating in IP space already staked out by a single incumbent, making freedom-to-operate assessment and design-around strategy essential before investing in this area.
The most recent one to two years of filing data are likely understated due to patent publication lag and should not be interpreted as a slowdown in activity. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Rapid expansion since 2021, with device-centric technology composition
Filing activity was negligible through 2020 and then surged sharply in 2021 and 2022, establishing this as an emerging-to-growth field. The technology mix is dominated by device and diagnostic classes, with informatics and control systems appearing as thinner but present branches.
Annual filing trend
Zero filings are recorded from 2017 through 2020, followed by a single filing in 2021 and a peak of nine in both 2022 and 2023. The 2024 and 2025 figures are almost certainly understated due to publication lag and should not be read as a reversal of the growth trend.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61M (devices for body fluids) is the dominant IPC branch, reflecting the hardware-centric nature of CGM-drug delivery integration. A61B (diagnosis and surgery) and A61K (medicinal preparations) form a secondary cluster, while G16H (healthcare informatics) and G05B (control and regulating systems) are present but sparse, pointing to relatively thin coverage of software-driven closed-loop control.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Single package automated drug delivery system
Disclosed herein is a combination of an automated insulin delivery system and a continuous glucose monitor integrated into a single, wearable package. The system may use any combination of delivery methods and detection methods, wherein the delivery methods include a cannula, a microneedle array, and a transdermal patch, and wherein the detection methods… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Predictive control based system and method for con… | 248 |
| 2 | Single package automated drug delivery system | 4 |
| 3 | Method for detecting occlusions in a fluid path us… | 1 |
| 4 | Automatic drug delivery system for delivery of a G… | 1 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the structural data means for R&D investment decisions
A small, fast-growing corpus dominated by one assignee creates a specific risk-and-opportunity profile. Engineers and strategists should weigh freedom-to-operate, white-space entry paths, and the geographic footprint before committing resources.
Growth stage with activity easing from 2022 peak
The field is classified as Growth: the recent three-year filing window sits well above the prior three-year window, representing a 1,700% uplift on a multi-year basis. However, annual volume has eased from its 2022 peak, and the most recent data points are further suppressed by publication lag. R&D investment made now would enter a field that is still expanding but no longer in its initial vertical climb.
Growth stageSingle-firm dominance creates high IP risk for new entrants
Insulet Corp holds 19 of 20 patent families in this corpus, giving it an unusually tight grip on the core IP. The remaining two filers — P S R Engineering College and the University of Virginia Patent Foundation — each hold one family, offering no meaningful competitive counterweight. Any new entrant must conduct thorough freedom-to-operate analysis against Insulet Corp’s portfolio before proceeding.
Extreme concentrationNo co-filing activity detected; individual inventors linked to academic work
The evidence shows no co-applicant filings in this corpus. However, several named inventors — Cobelli Claudio, Dalla Man Chiara, De Nicolao Giuseppe, Magni Lalo, and Raimondo Davide Martino — appear in association with A61M37 filings, suggesting academic or research-group contributions that have not yet manifested as formal co-assignee relationships. Formal industry-academic collaboration partnerships are not yet visible in the IP record.
No co-filing detectedEurope leads filings; U.S. and Canada form secondary markets
Europe (EPO) is the lead jurisdiction with six patent records, followed by Canada with five and the United States with four. Australia holds three records, while China, India, and WIPO (PCT) each account for one. The relatively thin U.S. coverage compared to EPO is notable given that Insulet Corp is a U.S.-headquartered entity, and may reflect a deliberate international-first filing strategy or pending U.S. publications.
Europe-led footprintGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Insulet Corp as sole industrial leader; academic filers at the margin
The player landscape is essentially a single-firm story. Insulet Corp entered as a new filer in the observed window and has built the only substantial CGM drug delivery patent portfolio among the corpus filers. Academic contributors are present at the single-family level.
Insulet Corp
Insulet Corp holds 19 patent families in this corpus and is classified as a new entrant in the recent filing window, having built its position rapidly since 2021. Its technology focus is concentrated in A61M 5 (devices for body fluids, 18 families), A61B 5 (diagnosis and surgery, 9 families), and A61K 38 (medicinal preparations, 9 families), reflecting an integrated hardware-diagnostic-pharmacological approach to CGM-coupled drug delivery.
families: 19P S R Engineering College
P S R Engineering College holds 1 patent family, with technology emphasis spread across A61B 5 (diagnosis and surgery), A61M 37 (devices for body fluids), and A61M 5 (devices for body fluids). As an academic institution with a single filing, it represents research-stage activity rather than a commercial competitive threat, but could be a source of licensing or collaboration opportunities.
families: 1| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Insulet Corporation | 18 | ▲ new entrant |
Under-served branches in therapeutic activity and closed-loop control
Two IPC branches sit at the sparse end of the technology distribution and are worth monitoring as potential adjacent areas. Both have plausible technical relevance to CGM drug delivery but currently show thin patent coverage relative to the dominant device-hardware classes.
A61P · Therapeutic activity of compounds
A61P covers the therapeutic activity of pharmacological compounds and accounts for only 4 patent records, representing 8% of the corpus. In a CGM-drug delivery context, this branch would capture compound-specific claims tied to glucose-responsive or adaptive dosing regimens. The sparse coverage suggests that the pharmacological dimension of closed-loop CGM systems — particularly beyond insulin analogs — remains largely unclaimed, offering a potential entry point for organizations with drug-device combination expertise. Entry would require demonstrating novel compound-activity relationships within an automated delivery architecture.
Search this in Eureka →G05B · Control & regulating systems
G05B addresses control and regulating systems and appears in only 1 patent record, representing 2% of the corpus — the sparsest branch identified. This branch would capture algorithmic control logic such as model predictive control, PID loops, and adaptive algorithms governing CGM-triggered drug delivery. The most-cited patent in this corpus is titled ‘Predictive control based system and method’ with 248 citations, signaling high technical value in this area despite thin patent coverage. Organizations with control-systems engineering capability may find meaningful white space here, particularly for next-generation closed-loop architectures.
Search this in Eureka →How filers differ by technology route across IPC branches
Strength of each leader across the main technology routes.
| Player | A61M 5 · Devices for body fluids | A61B 5 · Diagnosis & surgery | A61K 38 · Medicinal preparations | A61M 37 · Devices for body fluids | G16H 20 · Healthcare informatics |
|---|---|---|---|---|---|
| Insulet Corporation | Strong · 18 | Moderate · 9 | Moderate · 9 | Moderate · 5 | Moderate · 5 |
| P S R Engineering College | Strong · 1 | Strong · 1 | Absent | Strong · 1 | Absent |
Frequently asked questions
The corpus covers 20 patent families in the continuous glucose monitor drug delivery space, spanning the global filing record across the period analyzed.
Insulet Corp is the dominant filer with 19 patent families, representing near-total coverage of the corpus. P S R Engineering College and the University of Virginia Patent Foundation each hold one patent family.
Filings were negligible from 2017 through 2020, with one filing recorded in 2021 and a peak of nine filings in both 2022 and 2023. The 2024 and later data are likely understated due to publication lag.
Europe (EPO) leads with six patent records, followed by Canada with five and the United States with four. Australia holds three, while China, India, and WIPO (PCT) each account for one record.
The field is in a Growth stage. Recent three-year filings are substantially above the prior three-year window, representing a 1,700% uplift on a multi-year basis, though annual volume has eased from its 2022 peak and the most recent years are further understated by publication lag.
Yes. G05B (control and regulating systems), with only one patent record, and A61P (therapeutic activity of compounds), with four patent records, are the sparsest branches relative to the dominant A61M device class. Both have plausible technical relevance to advanced closed-loop CGM systems and represent areas of relatively thin incumbent coverage.
Ready to map your own CGM drug delivery patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.